Merck’s Vioxx Successor Arcoxia May Be Closer To Market
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA will need to weigh issues related to hypertension and length of the studies after preliminary results of massive trials show comparable cardiovascular events for etoricoxib and diclofenac.